Can smaller biotechs with limited resources develop their own assets in-house? One Chinese bioventure executive thinks so.
Lynk Pursues Own R&D Path But Partnerships Still Key
As tightening policies cast a shadow over Chinese bioventures relying mainly on in-licensing and shed fresh light on the importance of proprietary development, the CEO of one innovation-focused venture shares his views on strategy in an exclusive interview.
